


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutically[[-]] acceptable acid addition salt of a compound of formula I,



wherein

R^1 ~~represents is~~ C_{1-2} alkyl substituted ~~by~~ with one or more fluoro substituents;

R^2 ~~represents is~~ C_{1-2} alkyl; and

n ~~represents is~~ 0, 1, or 2.

2. (original) An acid addition salt as claimed in claim 1, wherein the acid is a sulfonic acid.

3. (currently amended) An acid addition salt as claimed in claim 1 ~~or claim 2~~, wherein the acid is methanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid, or *n*-butanesulfonic acid.

4. (currently amended) An acid addition salt as claimed in ~~any one of claims~~ claim 1 to 3, wherein R^1 ~~represents is~~ $-OCHF_2$ or $-OCH_2CH_2F$.

5. (currently amended) An acid addition salt as claimed in ~~any one of claims~~ claim 1 to 4, wherein R^2 ~~represents is~~ methyl.

6. (currently amended) An acid addition salt as claimed in ~~any one of claims~~ claim 1 to 5, wherein n ~~represents~~ is 0 or 2.

7. (currently amended) An acid addition salt as claimed in ~~any one of claims~~ claim 1 to 6, wherein the compound of formula I is
 $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$ or
 $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe)}$.

8. (currently amended) An acid addition salt as claimed in ~~any one of claims~~ claim 1 to 7 in substantially crystalline form.

9. (currently amended) An acid addition salt as claimed in ~~any one of claims~~ claim 1 to 7 in partially crystalline form.

10. (currently amended) An acid addition salt as claimed in ~~any one of claims 1 to~~ claim 8, wherein n ~~represents~~ is 0, ~~in substantially crystalline form~~.

11. (currently amended) An acid addition salt as claimed in ~~any one of claims 1 to 7 or claim 9~~, wherein n ~~represents~~ is 2, ~~in partially crystalline form~~.

12. (currently amended) An acid addition salt as claimed in ~~any one of claims 1 to 8 or claim 10~~, which is $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$ benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09, and 4.08 .

13. (currently amended) An acid addition salt as claimed in ~~any one of claims 1 to 7, claim 9 or claim 11~~, which is $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe)}$ hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69, and 3.63 .

14. (currently amended) A process for the preparation of an acid addition salt as claimed in any one of claims 1 to ~~13~~ 3, which process comprises addition of an acid to a compound of formula I ~~as defined in claim 1.~~

15. (currently amended) A process ~~for the preparation of an acid addition salt,~~ as claimed in claim 14, which process further comprises crystallising ~~an the~~ acid addition salt ~~as described in any one of claims 1 to 13.~~

16. (currently amended) A pharmaceutical formulation comprising an acid addition salt, ~~as claimed in~~ of any one of claims 1 to ~~13~~ 3, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

Claims 17-18 (cancelled)

19. (currently amended) A method ~~of treatment of~~ for treating a condition where inhibition of thrombin is required, ~~which method comprises administration of~~ comprising administering a therapeutically effective amount of an acid addition salt, ~~as claimed in~~ of any one of claims 1 to ~~13~~ 3, to a person suffering from, or susceptible to, such a condition.